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Gastric cancer remains a major cause of death in the
developed countries, and a large percentage is still genet-
ically unexplained. Because of their major role in cell
survival, mutations in translation factors and altered
expression of these genes have been associated with cancer
development. Apart from its role in translation termina-
tion, the eukaryotic translation release factor 3 (eRF3) is
involved in several critical cellular processes, such as cell
cycle regulation, cytoskeleton organization and apoptosis.
The aim of this study was to evaluate eRF3/GSPT1 gene as
a potential genetic susceptibility associated locus for
gastric cancer, analysing a stable GGC expansion in exon
1 encoding a polyglycine tract in the N-terminal domain of
the protein. DNA was obtained from 139 patients with
gastric cancer and from 100 individuals of a healthy
control population. The GGC expansion was amplified by
PCR and the number of repeats determined by genotyping
in an automatic sequencer. There are five known alleles
encoding from 8 to 12 glycines. The most common allele
encodes 10 glycines. The 12-Gly allele was detected exclus-
ively in the cancer patients (allelic frequency ¼ 5%).
Regardless of the genotype, patients with the 12-Gly allele
had a 20-fold increased risk for gastric cancer. We also
detected a single-base alteration in the gene (G274T)
although no correlation with cancer development has
been found. Thus, our results show that the GGC expan-
sion may have a potential role in regulating eRF3/GSPT1
expression and/or changing the protein function that can
lead to gastric cancer development.
Introduction
Because of its heterogeneity and multiple molecular altera-
tions in pathogenesis, the prognosis of gastric cancer remains
poor and a large percentage of tumours remain genetically
unexplained (1). Search for new biomarkers of gastric cancer
becomes imperative.
Trinucleotide repeat disorders are the most abundant forms
of repeat expansion diseases (2). Several exonic trinucleotide
repeats have been associated with oncological pathologies,
either conferring a protective effect or associated with elevated
risk for disease (3). The best-known examples are the androgen
receptor (AR) gene polymorphisms, a CAG and a GGC trinuc-
leotide repeats in exon 1, the length of which have been linked
to prostate cancer survival and breast cancer risk (4). However,
the molecular mechanisms underlying the polyglutamine
and polyglycine length modulation of AR function have not
been totally elucidated; results from different groups working
with different racial–ethnic populations are often inconclusive
and sometimes even conflicting (5). Furthermore, any causal
relation between the presence of a particular allele and the
development of cancer has been reported.
The importance of the translation machinery in cancer
development (6–8) is now widely recognized. Somatic muta-
tions and changes in the gene expression pattern of initiation,
elongation and termination translation factors have been
described associated with different types of cancer (9–12).
The eukaryotic release factor 3 (eRF3) has multifunctional
properties in eukaryotic cells. Beside its role in translation
termination (13,14), this protein was also reported to be
involved in cell cycle regulation (15,16), mRNA decay
(17,18), recycle of ribosomes (19) and apoptosis (20).
The N-terminal domain of eRF3 contains a polyglycine
expansion encoded by a stable (GGC)n tract in eRF3/GSPT1
exon 1 gene. There are five known alleles which encode 8, 9,
10, 11 and 12 glycines. This domain of eRF3 was shown to
lack critical regions for eRF1 binding, thus not being essential
to its role at the termination step of protein synthesis (21). The
N-domain of the protein interacts with the poly-A binding
protein (PABP) during translation reinitiation, which binds the
poly(A) tail of mRNA and also associates with the eukaryotic
initiation factor (eIF) 4G (17,22).
The aim of this study was to evaluate eRF3/GSPT1 gene as a
potential genetic susceptibility associated locus for gastric
cancer, analysing a stable GGC expansion in exon 1 encoding
a polyglycine tract in the N-terminal domain of the protein. As
it is involved in essential cellular processes, modifications in
the N-terminal domain of this protein might be of critical
relevance.
Materials and methods
We analysed the GGC repeat expansion in exon 1 of eRF3/GSPT1 in 139
individuals with gastric cancer (113 adenocarcinomas and 26 mucocellular
carcinomas), and compared with a control population of 100 healthy blood
donors, after informed consent was obtained.
DNA was extracted from peripheral blood using a phenol–chloroform
extraction (23). DNA from formalin-fixed paraffin-embedded tissues was
extracted using chelex resins (24). The DNA from fresh tissue was extracted
using the DNeasy Tissue Kit (Quiagen, Hilden, Germany) according to the
manufacturer’s protocol.
The (GGC)n fragment was PCR amplified using a 60-FAM labelled
forward primer (50-CATTTCTCGCTCTCTGTCCAC-30) and a non-labelled
reverse primer (50-CTGGTCCCAGCAGTCAGG-30) (25), being genotyped in
an ABI 310 sequencer and analysed with GeneScan 3.7 software (ABi,
Branchburg, NJ, USA). Reaction conditions for the fragment amplification
were 2.5 mM MgCl2; (Fermentas, Hanover, MD, USA) 2.5 mM dNTPs
(Fermentas, Hanover, MD); 2 Enhancer solution (Invitrogen, Carlsbad,
Abbreviations: AR, androgen receptor; eIF, eukaryotic initiation factor;
eRF3, eukaryotic translation release factor 3; PABP, poly-A binding protein.
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CA, USA); Taq Polymerase (Fermentas, Hanover, MD) 0.035 U/ml and the
primers’ concentrations were 0.4 mM. Cycling conditions were as follows: an
initial denaturation at 95C for 5 min, followed by 30 cycles at 95C for 1 min,
62C for 50 s and 72C for 1 min. At the end, there was a final extension step at
72C for 5 min.
Direct DNA sequencing of each detected allele was performed to confirm
the GGC repeat expansion.
Moreover, a mutation screening was carried out in all eRF3/GSPT1 exons,
exon–intron junctions and regulatory regions by PCR–SSCP using the primers
listed in Table I. All reactions were done according to the following conditions:
2.5 mM MgCl2 (Fermentas, Hanover, MD); 2.5 mM dNTPs (Fermentas,
Hanover, MD); 0.033 U/ml Taq Polymerase (Fermentas, Hanover, MD) and
0.2 mM of the primer concentration. Some fragments required the addition of
Enhancer solution 2 concentrated (fragments 0, 1a and 1b). Cycling condi-
tions were an initial denaturation step at 95C for 7 min, followed by 35 cycles
at 95C for 2 min, 55C for 1 min and 72C for 1 min. At the end, there was a
final extension step at 72C for 10 min.
The SSCP was carried under standard conditions as described in the
literature (23).
All statistical analyses were carried out using SPSS version 12.0.
Results
Five alleles were detected, which encode 8, 9, 10, 11 and 12
glycines; the 10-Gly allele being the most common in the
Portuguese population and the 12-Gly allele only found in
the cancer population.
Genotypic frequencies were in Hardy–Weinberg equilib-
rium in the control population (Fisher’s x2 P 4 0.05), but
not in the gastric cancer population (Fisher’s x2 P ¼ 0.0024).
Our results revealed significant differences between the gastric
cancer and control populations (x2 ¼ 15.486; P ¼ 0.002), the
12-Gly allele exclusive of the gastric cancer population (allelic
frequency ¼ 5%). A total of 8% of the patients studied presen-
ted the 12-Gly allele, meaning that it was found in homozygoty
in two cases. LOH was investigated and not detected in these
cases. Patients with the 12-Gly allele had a 20-fold increased
risk for gastric cancer (OR ¼ 19.933; 95% CI ¼ 1.179–333.94;
P ¼ 0.001) (Figure 1).
Significant differences were also observed in allelic frequen-
cies between gastric adenocarcinomas and mucocellular
carcinomas (x2 ¼ 34.881; P ¼ 0.001), the 12-Gly allele
being more frequent in the latter (allelic frequency ¼ 3.1
versus 13.5%). All the individuals that presented the 12-Gly
allele had gastric cancer independent of their genotype
(Figure 2), although only 12/12, 12/11 and 12/10 genotypes
were detected. Susceptibility for gastric cancer was shown not
to be associated with any particular genotype (see Figure 2).
We further investigated the presence of additional genetic
variability in eRF3/GSPT1 gene that could be linked with the
polyglycine expansion polymorphism. The eRF3/GSPT1 gene
of selected individuals who carried each allele was extensively
scanned by PCR–SSCP followed by direct sequencing when
adequate. We detected a thymine deletion in a stretch of
10 thymines in intron 5 (g24528–24529delT), adjacent to the
intron–exon junction, that might have influence in the splicing
process. Also, a synonymous nucleotide substitution in exon
14 was detected (G1755C).
Additionally, a nucleotide substitution G274T in exon 1,
resulting in an amino acid change from Gly to Cys at codon
92 was detected. We screened this mutation in a group of
gastric cancer patients and control individuals, and found no
significant differences in the frequencies between both groups
(x2 ¼ 0.04; P 4 0.05) (Table II). Odds ratio (OR) analysis
failed to reveal any risk/protective effect associated with either
allele. Moreover, the mutation did not segregate with any of
the alleles of the polyglycine expansion. Although genetic
databases revealed that this Gly is a conserved amino acid at
codon 92 of eRF3/GSPT1, our results provided evidence to
support that this is a polymorphism rather than a mutation
(Table III).
Discussion
Herewith we show, for the first time, a strong association
between a polymorphic trinucleotide repeat in a translation
factor and gastric cancer susceptibility. In addition, we found
a direct correlation between the presence of the 12-Gly allele
and gastric cancer. The molecular pathogenic pathway leading
to the cancer phenotype is still not elucidated. It can involve a
dominant gain of function effect by shifting the protein’s
conformation, thus altering its function or achieving toxicity.
This could have an effect on eRF3 functions namely at differ-
ent levels of translation regulation (13,14,17,19), in cytoskel-
eton organization, affecting chromosome segregation and
cytokinesis (26–28), or in apoptosis (20). Loss of function
can also occur, by interfering with transcription, RNA
processing or translation efficiency. Depletion of eRF3 has
Table I. SSCP primers sequence
Primer Sequence Fragment size (bp)
0 F ggtggttgggtgggaggag 212
0 R ggacagagagcgggaaatgg
1a F cagcagcagcagcgactc 208
1a R gaaggacggcacgaactc
1b F gtccacgccgccgagttc 181
1b R ccgcacccctacgccatg
2 F gattgaggcttgtgtcgtgttatt 231
2 R caaacagtatctagctttacacaccatat
3 F aggaacagtcattgtgtgaaggtaat 258
3 R tcgtaacttacataatgcaccttaaatctt
4a F aggaaatggaactacatatgcaaactt 409
4a R caggtagctaaaaaggatgttctatgttt
4b F catgggagcacaaagaagaaataag 261
4b R caggtagctaaaaaggatgttctatgttt
5 F ggatttatgccccaaattcatatg 256
5 R cctgttttatctcctttgtgtgactgta
6 F tctgacgttgaaattttcgacaat 253
6 R ttaacaggctccaaaagcactaagt
7 F aaaactctgatgttcttaggaatattgttc 271
7 R ctaacaaatatacagatggactggaaatg
8 F gaaggccaaggagtaaactgtttc 256
8 R aagtcgtacaataacaaaaccatcctta
9a F taaggatggttttgttattgtacgacttt 251
9a R tccgactgctctttgagatttg
9b F tcactttatgccctgctcag 133
9b R taagtaatttaagtaataacatccttttcc
10 F tttatgttgacttcctttaatggcttt 207
10 R aactagaaacaaaatgcacaacaatga
11 F atacagcaccaagaagtctgaaac 168
11 R tcaataaatagataggaaacagcataacc
12 F tatgttgcgtaatgcagtgaatgt 271
12 R cattaaaacccactatgacaacaacaa
13 F accctaaggctaaagataagaatgtg 143
13 R cttaaactcactgttatttccacctc
14 F ttggcattattctgattttctcatactct 272
14 R tgaagatgaccaaagctaggtatcct
15a F ggtttggcagtaaagctagttaattagtaa 267
15a R aaataagagaaggcggtgtgaagta
15b F cctacttcacaccgccttctc 425
15b R gctaatgcaacaatgttacatccag
Primer numbers correspond to the exon to which each primer belongs.
Fragment 0 belongs to 50 UTR. Small letters indicate exons that had to be
amplified in two fragments. All primers were designed using Primer3
Software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi).
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been recently shown to increase the read-through in HeLa cells
to the same extent as eRF1 depletion does, which can lead to a
pool of aberrant polypeptides in the cell (29,30). Also,
although not usual, downregulation of translation factors asso-
ciated with malignancies have been reported (31). Due to the
presence of CpG islands, aberrant DNA methylation patterns
may also occur leading to the inactivation of gene expression,
being the variation in the number of GGC elements causal for
the variability in the transcription level of the gene. A CCG
expansion has been proposed as the mechanism responsible for
the hypermethylation of the repeats and the adjacent CpG-rich
promoter in FMR1 gene, preventing the binding of trans-
cription factors and consequently leading to transcription
Fig. 2. Genotypic frequencies of the eRF3 polyglycine repeat length alleles in the gastric cancer patients and control individuals. Frequencies and odds ratio
analysis of the eRF3 repeat length polymorphism (Gly, glycine; OR, odds ratio; CI, confidence interval; P, P-value).
Table II. Odds ratio results for the polymorphism G274T in gastric
cancer patients when compared with a healthy control population
g t
Gastric cancer (N ¼ 15) 0.43 0.57





x2 not significant (P 4 0.05).
OR, odds ratio; CI, confidence interval.
Table III. Amino acid conservation at position 92 throughout several
organisms
Organism Partial eRF3 protein sequence
Homo sapiens A A E F V P S F L R G – P A A P P P P A G
Pan troglodytes A A E F V P S F L R G – P A A P P P P A G
Canis familiaris A A E F V P S F L R G – P A Q P Q T P A A
Mus musculus A A E F V P S F L R G – P A Q P P L S P A
Rattus norvegicus A A E F V P S F L R G – P A Q P P L S P A
Oryctolagus cuniculus A A E F V P S F L R G – P A P P P A P A G
Gallus gallus A A E F V P S F L R G A P A P G L P P P S
Polymorphic amino-acid in bold.
Fig. 1. Allelic frequencies of the eRF3 polyglycine repeat length alleles in the gastric cancer patients and control individuals. Frequencies and odds ratio
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repression. Subsequent to this expansion, FMR1 is silenced
causing fragile X syndrome (32). In the human AR, it was
suggested that a hairpin stability caused by GGC expansions
could interfere with translation, and lead to protein decrease
(33). As well, a short polyalanine expansion in PABP2 gene
causes nuclear filament inclusions in skeletal muscle fibres,
responsible for oculopharyngeal muscular dystrophy (34).
Most of the studies done so far on the role of genetic
variants’ contribution to gastric cancer highlighted individual
variations in cancer risk, associated with specific variant
alleles of different genes (polymorphisms) that are present in
a significant proportion of the normal population. In this study,
we report the presence of a specific allele directly associated
with gastric cancer development. Importantly, the molecular
mechanism associated with the presence of the 12-Gly allele in
eRF3/GSPT1 remains to be elucidated.
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